ArticleEndocrine2015
ACROSTUDY: the Italian experience.
Article in Endocrine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies.Endocrine · 2019Pooled it
- Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026Review
- Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.Pituitary · 2026Article
- Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis.Endocrine connections · 2024Article
- Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases.Scientific reports · 2022Article
- More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.European journal of endocrinology · 2021Article
- Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management · 2020Review
- Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.Frontiers in endocrinology · 2020Review
- Pegvisomant in acromegaly: a multicenter real-life study in Argentina.Archives of endocrinology and metabolism · 2019Observational
- How to improve effectiveness of pegvisomant treatment in acromegalic patients.Journal of endocrinological investigation · 2018Observational
- Article
- Pegvisomant in acromegaly: an update.Journal of endocrinological investigation · 2017Review
- Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.Pituitary · 2017Review
- Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.Pituitary · 2016Observational
- Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.Journal of endocrinological investigation · 2015Article
- Optimal use of pegvisomant in acromegaly: are we getting there?Endocrine · 2015Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ACROSTUDY is a world-wide non-interventional, post marketing surveillance study performed to monitor the safety and outcomes of pegvisomant (PEG) in clinical practice. We report data from acromegaly patients who have been included in the Italian ACROSTUDY registry. The data of 341 acromegaly patients (171 males) were available for analysis using data freeze (12/9/2012). Patients were enrolled in 25 Italian endocrine centres. Before and during PEG treatment IGF-I, liver enzymes, metabolic parameters, and pituitary MRI were assessed. Before PEG, 54.3% patients had been treated with medical therapy and surgery, 22.9% medical therapy only, and 15.8% medical plus radiation and surgical therapy. 199 adverse events were reported in 98 patients (28.7%). Serious adverse events were documented in 29 patients (8.5%). 71.1% of patients had no significant change in tumor volume. Central MRI reading was performed in 34 patients; in 7 patients, an increase in tumor volume was found. Hormonal efficacy progressively increased since the start of PEG. After 6 years, normal IGF-I levels were found in 70.9% of patients (mean daily dose 18.1 mg). 87.1% of patients were treated with daily PEG although in 8.8% of patients, it was administered 2-6 times per week and in 3.8% with weekly injections. 74.8% received a PEG dose 10-15 mg/daily. PEG is a drug with a favorable safety profile which is efficacious also considering that in Italy it is currently available as third-line therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.